News & Events

New Product Launch: Lumia 2 Smart Earrings

  • Post category:A30 - Lumia

Lumia is bringing their lightest wearable tech for measuring blood-flow to a whole new market with the introduction of a fine jewelry inspired smart-earring form factor with expanded health monitoring features. BOSTON – Nov. 18, 2025 – Lumia today announced the launch of Lumia 2, the world’s first smart earrings that continuously track real-time blood flow to your head, giving anyone instant insight into how blood flow affects energy, focus, and mental clarity. Originally developed with Johns Hopkins, Duke, and Harvard researchers to help patients with chronic blood flow disorders like POTS (Postural Orthostatic Tachycardia Syndrome) and Long COVID-19, Lumia is now available to everyone for the first time.Indistinguishable from fine jewelry, Lumia 2 can be worn as huggie hoops, cuffs, and studs offered in gold, silver, and clear finishes, and also attaches to any…

Continue ReadingNew Product Launch: Lumia 2 Smart Earrings

Award: Best Demo Audience Choice Award at IEEE BSN 2025

The team of Colin Barry, Tatsuo Kumamoto, Edward Wang, and Lina Battikha won the Audience Choice Award for Best Demo at the IEEE-EMBS International Conference on Body Sensor Networks – Computational Medicine: Expanding Health through Sensing and AI held from November 3-5, 2025 for their demo entitled, "Oscillometric Smartphone Blood Pressure Demo." Source: LinkedIn Post

Continue ReadingAward: Best Demo Audience Choice Award at IEEE BSN 2025

Past Webinar – Listening to the Heart: In-Ear Infrasonic Technology for Blood Pressure and Beyond

https://youtu.be/K8-TKfD6Hrs?si=bUiCRsvyCQ2sP4KR Abstract: This talk will highlight the results of MindMics’ recent feasibility study on non-invasive blood pressure monitoring using in-ear infrasonic signals. Dr. Barnacka will discuss how this novel technology, validated through clinical research, can be integrated into both consumer earbuds and hearing aids, creating a new class of connected health devices. The presentation will explore the underlying infrasonic science, algorithmic advances, and the broader impact on cardiovascular health, preventive care, and data-driven wellness ecosystems. Biography: Anna Barnacka, Founder and CEO, MindMics Inc. Dr. Anna Barnacka is the Founder and CEO of MindMics, a Boston-based healthtech company pioneering “In-Ear Infrasonic Hemodynography (IH)” — a patented technology that transforms earbuds and hearing aids into clinical-grade heart-health monitors. With dual PhDs in Physics and Astronomy and a NASA Einstein Fellowship at Harvard, Anna bridges physics, acoustics, and…

Continue ReadingPast Webinar – Listening to the Heart: In-Ear Infrasonic Technology for Blood Pressure and Beyond

Wearable Heart Failure Socks for Exacerbation and Treatment Monitoring

Pamela Z. Cacchione, University of Pennsylvania. Li Shen, University of Pennsylvania. Heart Failure Monitoring Socks will be used in hospitalized persons with heart failure to gather data on heart failure exacerbations and responses to treatment. We will use this data to develop predictive models for edema and fatigue due to heart failure.

Continue ReadingWearable Heart Failure Socks for Exacerbation and Treatment Monitoring

Voiceitt: AI-Enabled Speech Recognition for Older Adults with Severe Dysarthria

Katie Seaver, The Babel Group. Rachel Khasky-Levy, The Babel Group. This project will evaluate a personalized speech recognition app built by Voiceitt for adults aged 55+ with severe dysarthria, focusing on accuracy, usability, and user satisfaction. Participants will train the app on their own speech and use it in daily life, with support from The Babel Group.

Continue ReadingVoiceitt: AI-Enabled Speech Recognition for Older Adults with Severe Dysarthria

AI-Driven Drug Repurposing to Identify Potential Geroprotectors

Jesse Poganik, Brigham and Women's Hospital. This pilot project leverages artificial intelligence and advanced aging biomarkers to identify existing FDA-approved medications that may slow biological aging, using clinical data and biospecimens from over 155,000 participants in the Mass General Brigham Biobank. By focusing on approved drugs with established safety profiles, this approach enables rapid translation of findings into clinical practice for promoting healthy aging and preventing age-related diseases.

Continue ReadingAI-Driven Drug Repurposing to Identify Potential Geroprotectors